Clinical Trials

Taletrectinib is currently being evaluated in multiple Phase 2 clinical trials in first and second-line ROS1-positive NSCLC. The global Phase 2 trial TRUST-II is actively enrolling patients. The China Phase 2 trial TRUST has enrolled more than 100 patients. Two Phase 1 trials, one conducted in the US and the other study in Japan, have been successfully completed.

Taletrectinib for ROS1 fusion-positive NSCLC

Trial Title Trial Number Stage Status Publication

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)

NCT04919811

Phase 2, Global (US, Japan, Korea, Europe, Canada, and China )

Recruiting

ASCO 2022 Trial in Progress

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (TRUST)

NCT04395677

Phase 2, China

Recruiting

ASCO 2022 Efficacy and Safety Result Updates, as of Feb 23, 2022

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

NCT02675491

Phase 1, Japan

Completed

JTO 2021, pooled analysis of the two Phase 1 studies

CCR 2020, US phase 1 study

Oncotarget 2018, Japan phase 1 study

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433

Phase 1, US

Completed

JTO 2021, pooled analysis of the two Phase 1 studies

CCR 2020, US phase 1 study

Oncotarget 2018, Japan phase 1 study

Patient Access to Investigational Medicines

Contact Us

For questions about ongoing clinical trials, please contact trials@anhearttherapeutics.com.

“Taletrectinib (AB106/DS6051b) has shown meaningful clinical activity in patients with advanced ROS1+ NSCLC who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”

from Jan 2021, JTO Clinical and Research Reports.

still image of video, click to play.

Dr. Misako Nagasaka speaks about taletrectinib data, Nov 2021